Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Gilead Sciences, Inc. (GILD : NSDQ)
 
 • Company Description   
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Number of Employees: 14,400

 
 • Price / Volume Information   
Yesterday's Closing Price: $63.84 Daily Weekly Monthly
20 Day Moving Average: 8,700,014 shares
Shares Outstanding: 1,254.31 (millions)
Market Capitalization: $80,075.34 (millions)
Beta: 0.38
52 Week High: $74.12
52 Week Low: $57.19
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.14% 12.78%
12 Week 5.33% 15.79%
Year To Date -12.08% 6.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
333 LAKESIDE DRIVE
-
FOSTER CITY,CA 94404
USA
ph: 650-574-3000
fax: 650-578-9264
investor_relations@gilead.com http://www.gilead.com
 
 • General Corporate Information   
Officers
Daniel P. O'Day - Chairman and Chief Executive Officer
Andrew D. Dickinson - Chief Financial Officer
Diane E. Wilfong - Senior Vice President and Chief Accounting Officer
Jacqueline K. Barton - Director
Jeffrey A. Bluestone - Director

Peer Information
Gilead Sciences, Inc. (CORR.)
Gilead Sciences, Inc. (RSPI)
Gilead Sciences, Inc. (CGXP)
Gilead Sciences, Inc. (BGEN)
Gilead Sciences, Inc. (GTBP)
Gilead Sciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 375558103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 1,254.31
Most Recent Split Date: 1.00 (2.00:1)
Beta: 0.38
Market Capitalization: $80,075.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 4.57%
Current Fiscal Quarter EPS Consensus Estimate: $1.52 Indicated Annual Dividend: $2.92
Current Fiscal Year EPS Consensus Estimate: $6.60 Payout Ratio: 0.40
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: 0.04
Estmated Long-Term EPS Growth Rate: 21.50% Last Dividend Paid: 03/14/2022 - $0.73
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.68
Trailing 12 Months: 8.71
PEG Ratio: 0.45
Price Ratios
Price/Book: 4.02
Price/Cash Flow: 7.12
Price / Sales: 2.91
EPS Growth
vs. Year Ago Period: 1.92%
vs. Previous Quarter: 207.25%
Sales Growth
vs. Year Ago Period: 2.60%
vs. Previous Quarter: -9.03%
ROE
03/31/22 - 44.98
12/31/21 - 45.27
09/30/21 - 56.59
ROA
03/31/22 - 13.89
12/31/21 - 13.59
09/30/21 - 16.36
Current Ratio
03/31/22 - 1.48
12/31/21 - 1.27
09/30/21 - 1.37
Quick Ratio
03/31/22 - 1.30
12/31/21 - 1.13
09/30/21 - 1.20
Operating Margin
03/31/22 - 33.63
12/31/21 - 33.66
09/30/21 - 40.34
Net Margin
03/31/22 - 16.43
12/31/21 - 22.80
09/30/21 - 26.91
Pre-Tax Margin
03/31/22 - 21.34
12/31/21 - 30.32
09/30/21 - 33.96
Book Value
03/31/22 - 15.88
12/31/21 - 16.79
09/30/21 - 17.12
Inventory Turnover
03/31/22 - 4.07
12/31/21 - 3.86
09/30/21 - 3.11
Debt-to-Equity
03/31/22 - 1.31
12/31/21 - 1.24
09/30/21 - 1.22
Debt-to-Capital
03/31/22 - 56.75
12/31/21 - 55.39
09/30/21 - 54.90
 

Powered by Zacks Investment Research ©